PROK 241220 2.50C (PROK241220C2500) Stock Options, News & Quotes

0.20
+0.03+17.65%

15min DelayClose Nov 29 13:00 ET

0.21High0.20Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Nov 12 06:31

NEWS ER

$ProKidney (PROK.US)$
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
Positive
FDA confirmation that PROACT 1 Phase 3 study could be sufficient for full regulatory approval
Accelerated approval pathway available with eGFR slope as surrogate endpoint
Strong cash position of $406.8 million, supporting operations into 2027
Reduced R&D expenses by $0.9 million year-over-year
Slight improvement...

Jaguar8

Oct 22 16:50

Put alert 13Gs filed aftermarket

$ProKidney (PROK.US)$

Trytosaveabit

Oct 22 14:46

New 13G/A

$ProKidney (PROK.US)$ ProKidney | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Aaron Cowen(10.47%),Suvretta Capital Management, LLC(9.8%), etc.
SEC· 11 mins ago

Trytosaveabit

Oct 14 06:32

Watching for data outa dis! Hehehe

$ProKidney (PROK.US)$ Today announced that the Company will present five posters, including one late-breaking clinical trial, at the upcoming American Society of Nephrology's (ASN) Kidney Week being held on October 23-27, 2024, in San Diego, CA.

Trytosaveabit

Sep 3 06:33

Update

$ProKidney (PROK.US)$ Reuters· 2 mins ago
ProKidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S. Believes Phase 3 Regen-016 (Proact 2) Trial Is Not Required for Initial U.S. Registration